Latest news with #SBILifeInsurance
Mint
2 days ago
- Business
- Mint
Recommended stocks to buy today, 29 July, by India's leading market experts
On Monday, Nifty 50 declined 0.63% pressured by continued weakness in banking, financial, IT, and energy stocks amid lackluster corporate earnings. Persistent foreign institutional selling, driven by valuation concerns, further weighed on the index. Additionally, global uncertainty surrounding the India-US trade negotiations and the absence of fresh domestic triggers contributed to subdued investor sentiment. With muted earnings momentum and caution prevailing across sectors, the market remained under pressure throughout the session, reflecting a broadly negative undertone. On to the best stock picks for today, as recommended by leading market experts. Three stocks to trade, recommended by NeoTrader's Raja Venkatraman Why it's recommended: SBI Life Insurance, incorporated in October 2000, is a leading Indian life insurance company. It operates as a joint venture between the State Bank of India (SBI), India's largest commercial bank, and BNP Paribas Cardif S.A., the life and property and casualty insurance arm of BNP Paribas. Strong demand recovery in this stock from lower levels and the rebound from demand zones support price stability and growth potential. With prices trading close to the 52-week high, more room for upside is possible. Key metrics: P/E: 74.55 52-week high: ₹1,936, Volume: 1.18M. Technical analysis: Support at ₹1,730, resistance at ₹2,050. Risk factors: Dependence on trends in the insurance sector and raw material price volatility. Buy at: CMP and dips to ₹1,810. Target price: ₹1,950-2,000 in 1 month. Stop loss: ₹1,790. Why it's recommended: Signs of reversal from oversold zones signal potential upside. Demand at lower levels showcases optimism for recovery in the coming sessions. The daily charts indicate that the volume-based rise seen in the last few sessions augurs well for the prices. Key metrics: P/E: 46.88 52-week high: ₹262.50 Volume: 1.86M Technical analysis: Support at ₹165 | Resistance at ₹205. Risk factors: Declining revenue and profits, as well as a decrease in operating profit margin. Buy at: CMP and dips to ₹177. Target price: ₹190-195 in 1 month. Stop loss: ₹174. Why it's recommended: Gradual accumulation at critical support levels highlights strong investor interest, supported by consistent revenue growth. Steady higher lows with a thrust above value area resistance around 300 suggest more upside possibility. Key metrics: P/E: 67.18 52-week high: ₹1,632 Volume: 118.49K Technical analysis: Support at ₹1,470 | Resistance at ₹1,850. Risk factors: Competition in the banking space and regulatory issues. Buy at: CMP and dips to 1640. Target price: ₹1,770-1,825 in 1 month. Stop loss: ₹1,620. MarketSmith India's Best stock recommendations for today Buy: Cipla Ltd (current price: ₹1,572) Top 3 stocks recommended for today by Ankush Bajaj Why it's recommended: The stock has shown strength by closing 1.36% higher in the previous session despite a broader market sell-off. The daily RSI is at 63 and the MACD is above the zero line, both indicating increasing bullish strength. Once the stock sustains above ₹1,320, the setup suggests a potential breakout toward fresh lifetime highs. Breakout zone: Sustained move above ₹1,320 could open new highs Pattern: Strength continuation against broader market weakness MACD: Positive and rising above zero line RSI: Daily RSI at 63, suggesting bullish momentum Technical analysis: With strong momentum and resistance nearing breakout levels, the stock appears poised for an upward continuation toward ₹1,355 in the near term. Risk factors: A close below ₹1,264 will invalidate the current bullish setup and may signal short-term weakness. A disciplined stop-loss at ₹1,264 is recommended Buy at: ₹1,295.80 Target price: ₹1,355 Stop loss: ₹1,264 Why it's recommended: ICICI Bank stock is showing strong bullish momentum with the daily RSI at 65 and MACD at 13. On lower time frames, the stock has formed a solid base around ₹1,474, which is expected to support further upward movement. The setup suggests potential for a short-term rally toward ₹1,504. Breakout zone: Built a firm base at ₹1,474 on lower timeframes Pattern: Base formation with follow-through momentum MACD: Positive at 13, showing strong trend strength RSI: Daily RSI at 65, indicating positive momentum Technical analysis: With solid momentum and base formation in place, ICICI BANK appears well-positioned to rally toward ₹1,504 in the near term. Risk factors: A close below ₹1,480 will invalidate the current bullish setup and may signal short-term weakness. A disciplined stop-loss at ₹1,480 is recommended Buy at: ₹1,488.40 Target price: ₹1,504 Stop loss: ₹1,480 Why it's recommended: Cipla stock has broken out of a rectangle consolidation pattern on the daily chart, confirming bullish continuation. The daily RSI is at 70 and MACD at 5, both pointing to strong underlying momentum. This technical setup supports further upside toward the ₹1,615 level. Breakout zone: Rectangle breakout confirmed on daily chart Pattern: Consolidation breakout with momentum confirmation MACD: Positive at 5, showing a strong uptrend RSI: Daily RSI at 70, reflecting bullish strength Technical analysis: With the price breaking out from a defined range and supported by strengthening momentum, the stock is favorably positioned for a move toward ₹1,615. Risk factors: A close below ₹1,548 will invalidate the current bullish setup and may signal short-term weakness. A disciplined stop-loss at ₹1,548 is recommended Buy at: ₹1,572.00 Target price: ₹1,615 Stop loss: ₹1,548 MarketSmith India is a stock research platform and advisory service focused on the Indian stock market. Trade name: William O'Neil India Pvt. Ltd. (Sebi Registered Research Analyst Registration No.: INH000015543) Ankush Bajaj is a Sebi-registered research analyst. His registration number is INH000010441. Raja Venkatraman is co-founder, NeoTrader. His Sebi-registered research analyst registration no. is INH000016223. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by Sebi and certification from NISM in no way guarantees performance of the intermediary or provide any assurance of returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
5 days ago
- Business
- Business Standard
SBI Life Insurance registers New Business Premium of Rs. 7,268 crores for the period ended on 30th June, 2025
PRNewswire Mumbai (Maharashtra) [India], July 25: SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of Rs. 7,268 crores for the period ended on 30th June, 2025 vis-a-vis Rs. 7,033 crores for the period ended June 30, 2024. Regular premium has increased by 12% over the corresponding period ended on 30th June, 2024. Establishing a clear focus on protection, SBI Life's protection new business premium stood at Rs. 980 crores for the period ended June 30, 2025. Protection Individual new business premium stands at Rs.165 crores for the period ended June 30, 2025. Individual New Business Premium stands at Rs. 4,939 crores with 4% growth over the corresponding period ended on 30th June, 2024. SBI Life's profit after tax stands at Rs. 594 crores for the period ended June 30, 2025 with a growth of 14% over the corresponding period last year. The company's solvency ratio continues to remain robust at 1.96 as on June 30, 2025 as against the regulatory requirement of 1.50. SBI Life's AUM also continued to grow at 15% to Rs. 4,75,813 crores as on June 30, 2025 from Rs. 4,14,772 crores as on June 30, 2024, with the debt-equity mix of 60:40. 94% of the debt investments are in AAA and Sovereign instruments. The company has a diversified distribution network of 323,838 trained insurance professionals and wide presence with 1,146 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of sale persons (POS), insurance marketing firms, web aggregators and direct business. Performance for the period ended June 30, 2025 * Private Market leadership in IRP & Ind. NBP with market share of 22.3% & 25% respectively. * Annualized Premium Equivalent (APE) stands at Rs. 3,969 crores with growth of 9%. * Individual New Business sum assured stands at Rs. 66,631 crores with 73% growth. * Improvement in 13M & 61M persistency by 58 bps & 501 bps respectively. * Value of New Business (VoNB) stands at Rs. 1,088 crores with a growth of 12%. * VoNB Margin stands at 27.4%. * Indian Embedded Value (IEV) stands at Rs. 74,257 crores with growth of 20%. * Profit After Tax (PAT) stands at Rs. 594 crores with 14% growth * Robust Solvency ratio of 1.96 * Assets under Management stands at Rs. 4,75,813 crores with 15% growth About SBI Life Insurance SBI Life Insurance ('SBI Life' / 'The Company'), one of the most trusted life insurance companies in India, was incorporated in October 2000 and is registered with the Insurance Regulatory and Development Authority of India (IRDAI) in March 2001. Serving millions of families across India, SBI Life's diverse range of products caters to individuals as well as group customers through Protection, Pension, Savings and Health solutions. Driven by 'Customer-First' approach, SBI Life places great emphasis on maintaining world class operating efficiency and providing hassle-free claim settlement experience to its customers by following high ethical standards of service. Additionally, SBI Life is committed to enhance digital experiences for its customers, distributors and employees alike. SBI Life strives to make insurance accessible to all, with its extensive presence across the country through its 1,146 offices, 27,040 employees, a large and productive network of about 253,799 agents, 62 corporate agents and 9 bancassurance partners with more than 41,000 partner branches, 150 brokers and other insurance marketing firms. In addition to doing what's right for the customers, the company is also committed to provide a healthy and flexible work environment for its employees to excel personally and professionally. SBI Life strongly encourages a culture of giving back to the society and has made substantial contribution in the areas of child education, healthcare, disaster relief and environmental upgrade. In 2024-25, the Company touched over 53,000 direct beneficiaries through various CSR interventions. Listed on the Bombay Stock Exchange ('BSE') and the National Stock Exchange ('NSE'), the company has an authorized capital of ' 20.0 billion and a paid up capital of ' 10.0 billion. The AuM is ' 4,758.1 billion. For more information, please visit our and connect with us on Facebook, Twitter, YouTube, Instagram, and Linkedin. (Numbers & data mentioned above are for the period ended June 30, 2025) Logo:
Business Upturn
5 days ago
- Business
- Business Upturn
Nifty top gainers today, July 25: Cipla, SBI Life, Apollo Hospitals, Dr. Reddy's Laboratories and more
By Aman Shukla Published on July 25, 2025, 15:36 IST Indian markets ended in the red on July 25, with the Sensex falling 721 points to 81,463.09 and the Nifty slipping 225 points to close at 24,837. Despite the broad sell-off, select Nifty 50 stocks managed to buck the trend and closed in positive territory. Below is a detailed look at the top gainers of the Nifty 50 (as per Trendline) for the day. Nifty 50 Top Gainers on July 25 Cipla closed at ₹1,535, up 3.2% SBI Life Insurance ended at ₹1,830.7, up 2.1% Apollo Hospitals settled at ₹7,474, up 1.5% Dr. Reddy's Laboratories closed at ₹1,277, up 0.9% Sun Pharmaceutical finished at ₹1,702, up 0.6% HDFC Life Insurance ended at ₹760.1, up 0.4% Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Apollo HospitalsCiplaDr Reddy's LaboratoriesSBI LifeStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
SBI Life rises 2% on posting Q1 results; Should you buy, sell or hold?
SBI Life Insurance Q1 results review: SBI Life shares rose 2.4 per cent in trade on Friday, on the BSE, after the company posted its Q1 results. The stock logged an intra-day high at ₹1,843.15 per share. At 9:26 AM, SBI Life share price was trading 2.19 per cent higher at ₹1,837.7 per share on BSE. In comparison, BSE Sensex was down 0.5 per cent at 81,770.19. The market capitalisation of the company stood at ₹1,84,227.16 crore. SBI Life Q1FY26 results SBI Life Insurance reported a 14 per cent growth in net profit to ₹590 crore for the June quarter of the current financial year. The company's profit after tax stood at ₹520 crore in the April-June quarter of the previous financial year. The company's new business premium of the insurance firm rose to ₹7,270 crore during the period under review, compared to ₹7,033 crore in the June 2024 quarter. Its renewal premium has increased 24 per cent to ₹10,550 crore as against ₹8,540 crore in the corresponding period ended on June 30, 2024. Asset Under Management (AUM) grew 15 per cent from ₹4,14,770 crore as on June 30, 2024, to ₹4,75,810 crore as on June 30, 2025, with a debt-equity mix of 60:40, it said. SBI Life Q1 results analysis: Emkay Global Financial Emkay Global Financial Services has maintained a 'Buy' on SBI Life with an unchanged target of ₹2,100 per share, given the favourable risk reward. SBI Life's Q1FY26 performance was impressive, with a healthy Value of New Business (VNB) margin of 27.4 per cent, up by 60 basis points (bps) year-on-year (Y-o-Y) as against the estimate of 27.5 per cent and 27 per cent, respectively, according to the brokerage. 'The market seems to be underappreciating its sustained performance delivery, which echoes in its FY17-25 numbers – it has compounded EV and VNB at 19.8 per cent and 24.4 per cent, respectively, without any external capital infusion while seeing interest rate movements, equity volatilities, and the Covid-19 shock,' the brokerage note read. SBI Life Q1 analysis: Nuvama Institutional Equities The brokerage continued with a 'Buy' rating and raised its target price to ₹2,250 per share from ₹2,100. SBI Life reported muted Q1FY26 individual Annualised Premium Equivalent (APE) growth of 6.4 per cent Y-o-Y due to a slowdown in linked products, while group APE surged 38.1 per cent Y-o-Y. VNB margin improved 60 bps Y-o-Y to 27.4 per cent as the mix came in favour of higher-margin business. This led to VNB expansion of 11.7 per cent Y-o-Y at ₹1,090 crore, up 6.2 per cent as compared to the brokerage estimate. 'We are maintaining FY26E/27E VNB, but increasing target valuation to 2.3x FY27E P/EV,' Nuvama said.
Time of India
5 days ago
- Business
- Time of India
SBI Life shares jump 3% after 14% YoY rise in Q1 profit. Should you buy?
SBI Life reported a 14% YoY rise in Q1FY26 net profit to Rs 594 crore, with net premium income up 14% to Rs 17,178 crore. First-year and renewal premiums showed YoY growth but fell sequentially. Motilal Oswal maintained a 'Buy' rating with a Rs 2,140 target, citing improving VNB margins and strong APE and VNB growth outlook. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of SBI Life Insurance Company jumped 2.5% to an intraday high of Rs 1,843.15 on the BSE on Friday, July 25, after the life insurer reported a 14% year-on-year (YoY) growth in net profit for the first quarter of the current financial year (Q1FY26). The company's profit after tax (PAT) rose to Rs 594 crore in the June premium income also increased 14% YoY to Rs 17,178 crore, compared to Rs 15,105 crore in Q1FY25. However, both PAT and premium income saw a sequential decline; PAT fell 27% from Rs 814 crore in Q4FY25, while net premium income dropped 28% from Rs 23,861 crore in the previous its business segments, SBI Life 's first-year premium stood at Rs 3,539 crore, down from Rs 4,859 crore in Q4FY25, but higher than Rs 3,146 crore in Q1FY25. Renewal premium for the quarter came in at Rs 10,546 crore, marking a 28% sequential drop from Rs 14,680 crore but a 23% YoY increase from Rs 8,539 what brokerages said post Q1 show:The domestic brokerage maintained its Buy rating on SBI Life Insurance , with a target price of Rs 2, brokerage noted that a shift in the product mix toward non-linked products is supporting improved Value of New Business (VNB) margins. The company has reiterated its guidance for mid-teen Annualized Premium Equivalent (APE) growth for expects VNB margins to remain in the 26–28% range. Motilal Oswal projects SBI Life to deliver a 16% APE CAGR and 19% VNB CAGR over FY25– brokerage added that its estimates remain unchanged, and the company's strong growth outlook is has maintained a 'Buy' rating on SBI Life Insurance with a revised target price of Rs 2,250, up from Rs 2, brokerage noted that strong margins contributed to an earnings beat in the recent quarter. Management is targeting mid-teens Annualized Premium Equivalent (APE) growth and a Value of New Business (VNB) margin of 26–28% for SBI Life is revamping its protection portfolio and plans to launch a new money-back product in the participating (PAR) segment. While the FY26E and FY27E VNB estimates remain unchanged, the target valuation has been raised to 2.3x FY27E P/EV.
